Member Info for bignose58

We can’t disagree with that Kendall.

Bothwell,

I heard you the first time.

But you’ll notice there were no huge buys or sells just lost of small 1x, 2x and 3x 10k lots. Not much in the way of free float.

Morning The.Italian.

Yup up n down faster than a H**s drawers ............. ;-)

They may even be selling out and immediately buying bay in through different traders. It’s all go at the HK casino. Up 7% as I write…. What next… :-O

Well, the sp is certainly not reflecting the statement made in the recent announcement with many shareholders (I suspect local) jumping ship.

It is probably due to Beijing recently cracking down on cross boarder trading apps. Although it would seem the authorities are doing this have better control, it is not stopping investors selling out to prevent heavy fines. Once a new doorway becomes available, they will probably jump bs k in, but not before they have sold out to see what happens next.

Certainly seems RPG unfortunately made the announcement at the wrong time allowing for a near 80% increase and for shareholders to sell out.

Just my thoughts, but it could be the reason for the sudden pullback. Down another 10% at this moment in time.

https://www.channelnewsasia.com/commentary/china-economy-investment-app-broker-hong-kong-6188866

Kendall.

Yes, all very interesting. I did wonder when I saw they voted against the move to HK. I just wish I had seen the light and did the same. Unfortunately, like I suppose many others, I was sucked into the idea of becoming a billion dollar leader and of course because Dr Mike encouraged us all. Little did I also realise at the time that Dr Mike wasn’t interested in becoming wealthy, he was much more suffering from Pronoia. And more concerned about getting FDA approval. He emailed me so many false starts about “keeping US pharma HOT” and “a license agreement was going to happen in the coming months” (that was several years ago) that he forgot about the shareholders who stumped up the cash which kept the company going in the early days. I suspect, and this is just speculation on my side, he was also driven from not receiving global recognition for the little blue pill and needed recognition for Fortacin. He now appears to have fallen by the wayside and will not receive any recognition for it. There is no longer any mention of there being a scientific officer, let alone Dr Mike. And even when there was, he was only recognised for Fortacin and nothing else within the company .ie. DBS/Yooya and the DLI.

Kendal,

Maybe it has some connection with the South Korean arrest warrant that was issued for JM several years back for market manipulation. I think I remember reading somewhere that JG dismissed knowledge of it when interviewed.

Suffice to say, JM never went back to contest it and, again, I think I read somewhere that his South Korean associate became the fall guy.

As far as I am aware the warrant has now expired, although I am sure he will never want to set foot in that part of Asia again.

Try googling it as I'm sure you can still find ref to it, if you are interested.

Actually,

It will be interesting to see the half yearly figures, due out in several weeks, have changed and if the EU royalty income stream has increased.

Incidentally,

The company has on previous occasions (annual reports) mentioned about other pharmaceutical and life science products. They have previously stated ,after a placing that some of the monies would be used as capital in other sub-companies (all non-existent) , This apparently was to appease the local authorities , if they ever read one of the annual reports.

The.Italian.

Some figures for you.

The company states that it has now transitioned into a commercial-stage biopharmaceutical leader, which we know is utter BS since Senstend/Fortacin contains no living cells or biological systems and is therefore not a biopharmaceutical product. The only link is with the Wangbang name ie Biopharmaceutical Ltd. (what does that actually mean anyway if it is selling non biopharmaceutical drugs ?).

RPG is number 120 on the HK STX list of pharmaceutical companies, so nowhere near a "Leader" and looking at the market caps of the upper echelon of companies , is nowhere near achieving such a status any time soon. or for a long time, if ever.

Looking at Europe:

The E5 has a population of around 350mill which equates to 43.75 mill sufferers (12.5% of total population) and correct me if I am wrong, but RPG is currently making about 250k USD from commercial sales, which if considered as 20% of total receipts is about 1.25mill USD total sales (this is still far less than the German study which indicated only 14% [6.125mill] of sufferers who would actually seek help), i.e a reduction of 80% on the 6.125mill

In China, salaries are about 1/3rd of those in Europe, meaning that even less sufferers will want to pay the money, especially in the current Chinese financial climate and that's also considering that its now OTC in Europe and a still a script drug in China which will just make it more inaccessible.

So, based on the above, it would seem to me that sales in China will more than likely be no better (&% wise) than Europe which means further dilution for continued operation come next June and certainly means it will take many years before the company is in the upper echelon of companies and considered a market leader.

Of course, if there is indeed some genetic difference with regard to EP between Chinese and Europeans and Genetic can manufacture and provide more cans than shareholders are currently led to believe, I could be wrong, but certainly current indicators would indicate otherwise.

Obviously I am happy to be proven wrong, if anyone wants to do their own research which contradicts the above.

Morning The.Italian, I wasn't meaning to criticise, just for other readers who may have misunderstood since you are one of the more reliable posters :-)

Anyway, my concern is more with regard timing since all information given by the company as announcements or via direct emails indicate they have not considered things in detail with respect to when things should happen and what quaintly of product is available, which, is quite apparent from their comment "marking its successful transition into a commercial-stage biopharmaceutical leader". They seem to think they will make millions in the first year by stating "commercial-stage biopharmaceutical leader". The companies current market cap is a mere 27mill squid, which is nothing. with just a minor reaction by the market (yes, I state minor since we are still below the SP 1 year ago when we had a lot less going for us.)

The timing is such that could they deliberately be looking for yet another dilutionary share issue (with the aim of selling cheap shares to institutions ?). I am sorry but I just don't trust them, its has become painfully clear they don't give a monkeys asre about private investors otherwise we would have had FDA approval by now, they would have been more transparent about can production and they make BS statements as above, which doesn't fool anyone except the authorities who obviously have been blind to all the past BS contained in announcements and half yearly/annual reports.

There has been no mention of any market research by Wangbang to provide a different picture to that of the EU launch. Why would Local Chinese be mor willing in buying the product than a European ?.

Ok, we wait and see, but what they write is certainly not what I feel is to be expected.

The.Italian,

Regent didn’t get the Chinese approval, Wangbang did. If Regent had had any input to the process, the approval would have been delayed another 3 years….. at least. Regent got it delayed by 1-1/2 years as it is, due to their incompetence with respect to PSNW.

As I mentioned, past history has impacted shareholder confidence in a big way and I don’t expect it to be a lot better anytime soon.

Approx 3 months (which I doubt) till supposed can sales start. Only a limited number of cans available, based on the last update of 40k can production every 4 months. I suspect this year will see very little income from sales. Yes, there is the 7 mill USD which no doubt will be used to pay off Jim’s 7mill USD.loan. There is, according to the end of year results, enough cash to last till next June. Next year they need to make 2.25 mill USD in sales to break even just for that year.

What we and the market needs to see is can production so we have some idea on possible expected sales figures. Quoting a 9 mill target means nothing without the Added can supply.

Also, I wonder what sort of sales figures the other, already approved, product is currently making ?

The future is not as roses as they make out.

And posting BS Like this doesn’t help => “This approval represents a major inflection point for the Company marking its successful transition into a commercial-stage biopharmaceutical leader”, Biopharmaceutical leader !!! What utter tosh.

Show us the money…..

I really don’t think it will make much difference. The EU approved the drug and has data for thousands of subjects, they have also approved it as OTC which also indicates no subject issues. And remember initially the unambiguous FDA agreement meant RPG made the statements that approval would be given by June 2017. This date was obviously possible due to limited study requirement. Then it all changed and PLE had to jump through hoops to get even where we are today. Since We are heading towards phase iii, which is considered a minor requirement compared to phase II, I am sure they will want to see it to the end.

Note: One of the reasons it’s taken so long from the start of phase II is because RPG didn’t have the money. This was quite apparent when shareholders were advised the phase II 15 month study would end after only 12 months. Most thought it was good news meany 75% of subjects had been processed, however. At the end of the study, shareholders were informed on 15 subjects were processed. Then Jim injected 10 mill USD and the remaining subjects could be recruited and processed which all happened within the 2020 covid year.

That is also why it has taken over 18 months and still no license agreement to finish phase iii. RPG would rather lose 3mill squid on the DBC and pay 3.79 mill USD for the DLI, which is still not generating an income, rather than get the FDA approval over the line.

As Dr Mike told me 3years ago, if JG had given him the money when he asked for it, the FDA approval would have been given by then, hence the earlier approval dates shown in the presentations which were produced by Dr Mike.

So no, I don’t think it will make any difference.

Looks to me like they need to fire their reporter. Since when did RPG change their name back to Endurance RP ?

Regent Pacific Group, now known as Endurance RP ???

Anyone spot the mistake ? :-O

In my over zealous state, I made the mistake of comparing shares traded today with those when Fortacin was launched in the UK (Nov 2016). Hopefully when we are advised of the launch in China, it will pick-up by the same amount, although todays showing was still rather disappointing given the potentially huge market.

Nuff said.

Ex-sparky,

you are indeed correct. unfortunately the company has a long way to go to build confidence levels.

The China approval announcement should have been considered a big ticket item , however only 1.5% of the total number of shares were traded and only 5% of shares held by private investors.

Quite a difference when the company announced EU approval E5.

We now wait and see if sales are as expected or will they be as the EU which have been very disappointing (somewhat like Eroxon)

And the 78% rise today only pushed the SP up to a point which is still 4.67% lower than at this same time last year.

So... ended up 78% and a market cap of approx. 28.4mill GBP certainly not mind blowing

Volume today was 4.4mill shares. That's 1.5% of the total shares in the company, which is absolute pants when compared to more than 100% of shares traded after the EU approval announcement.

As a comparison of the 30% of shares held privately, that's a mere 5 %, which is also pant, only slightly bigger :-O